Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer

We evaluated the analytical and clinical performance of a novel circulating tumor cell (CTC)-based blood test for determination of programmed death ligand 1 (PD-L1) protein expression status in real time in treatment-naïve non-small cell lung cancer (NSCLC) patients. CTCs were detected in 86% of pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yen-Lin, Huang, Wen-Chien, Lin, Feng-Ming, Hsieh, Huangpin B., Hsieh, Chia-Hsun, Hsieh, Ruey Kuen, Chen, Kuo-Wei, Yen, Ming-Hong, Lee, James, Su, Stephen, Marfatia, Twinkal, Chang, Shih-En, Sundar, Padma, Patterson, Bruce, Watson, Drew, Mei, Rui, Javey, Manana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584214/
https://www.ncbi.nlm.nih.gov/pubmed/31089757
http://dx.doi.org/10.1007/s00262-019-02344-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584214/
https://www.ncbi.nlm.nih.gov/pubmed/31089757
http://dx.doi.org/10.1007/s00262-019-02344-6

Ejemplares similares